Loading
Quest Diagnostics Inc Stock: price and insider trades · United States
Quest Diagnostics Inc: what insiders have been doing
Headquartered in Madison, United States, Quest Diagnostics Inc belongs to the Healthcare & Pharma sector and traces its origins to 1967. Filings by its managers are published through SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Quest Diagnostics Inc logged 69 filings by 19 insiders.
All open-market trades in the period are sales: 6 sales worth €7.3M, by 4 insiders, with no purchase on record. Prevoznik Michael e filed the largest sale, €3.3M, on 31 August 2026, which represents 0.015% of the company's market value.
Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For context, the typical company on the same exchange (median of 5,810 companies) published 19 filings over the same period, against 69 filings here. Looking back to 2016, when coverage begins, insiders filed no purchases and 26 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of 992.0 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
333
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€13M
26 ops. · all time
Who traded when
BuySaleMichael E. Prevoznik4 sales
Delaney Mark e3 sales
Patrick Plewman3 sales
Doherty Catherine T.2 sales
J. E. Davis2 sales
Vicky B. Gregg2 sales
+2 other insiders
Analyst consensus: bullish or bearish?
Analysts rate Quest Diagnostics Inc Buy (bullish), based on 15 analysts. Average price target: US$248.80.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 10,382 of 24,148 companies
55.1
score / 100
Value53
Quality57
FCF yld5.2%
Earn yld3.8%
EV/EBITDA15.0x
ROE15%
Gross mgn33%
Net mgn9.0%
Debt/EBITDA3.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$233.43
Analyst consensus
15 analystsBuy
US$204.00Target US$248.80(+7%)US$265.00
Income statement
RevenueUS$11B
Gross profitUS$3.7B33% margin
EBITDAUS$2.2B20% margin
Net incomeUS$992M9.2% margin
Valuation
PER (trailing)24.8x
PER (forward)19.4x
P/Book3.4x
Beta0.54
Balance sheet & cash
Market capUS$25.8B
Total debtUS$6.6B
Free Cash FlowUS$1.4B
Debt / Equity81%
Profitability & ownership
ROE14.6%
ROA6.4%
% insiders0.4%
% institutions98.7%
Last declaration on 3 September 2026
Declarations333 total
10,000 shares@ US$242.720.0092% mcap8.0% of flowCommon StockSEC:0001599837-26-000007:0
22,677 shares@ US$112.170.0097% mcap6.8% of flowCommon StockSEC:0001022079-26-000089:0
16,010 shares@ US$242.87550.015% mcap10.4% of flowCommon StockSEC:0001022079-26-000089:1
6,237 shares@ US$243.62750.0058% mcap4.1% of flowCommon StockSEC:0001022079-26-000089:2
430 shares@ US$244.51480.0004% mcap0.3% of flowCommon StockSEC:0001022079-26-000089:3
1,000 shares0Common StockSEC:0001022079-26-000089:4
22,677 shares@ US$243.11340.021% mcap14.8% of flowCommonSEC144:0001959173-26-006526
1,600 shares@ US$235.180.0015% mcap9.1% of flowCommonSEC144:0001959173-26-005388
6 shares@ US$206.8130.0000% mcap26.2% of flowCommon StockSEC:0001022079-26-000080:0
11 shares@ US$206.8040.0000% mcap33.0% of flowCommon StockSEC:0001022079-26-000085:0
34 shares@ US$206.8070.0000% mcap0.2% of flowCommon StockSEC:0001022079-26-000079:0
72 shares@ US$206.8080.0001% mcap1.5% of flowCommon StockSEC:0001022079-26-000084:0
37 shares@ US$206.8070.0000% mcap0.1% of flowCommon StockSEC:0001022079-26-000086:0
21 shares@ US$206.810.0000% mcap100.0% of flowCommon StockSEC:0001022079-26-000082:0
46 shares@ US$206.8070.0000% mcap0.2% of flowCommon StockSEC:0001022079-26-000083:0
8,147 shares@ US$200.000.0070% mcap28.7% of flowCommonSEC144:0001959173-26-004345
1,142 shares0Common StockSEC:0001197607-26-000005:0
1,142 shares0Common StockSEC:0001527766-26-000002:0
1,142 shares0Common StockSEC:0001510304-26-000005:0
7 shares@ US$194.6990.0000% mcap19.1% of flowCommon StockSEC:0001022079-26-000047:0
39 shares@ US$194.6990.0000% mcap0.1% of flowCommon StockSEC:0001022079-26-000045:0
68 shares@ US$194.6980.0001% mcap1.3% of flowCommon StockSEC:0001022079-26-000048:0
25 of 333 declarations
About Quest Diagnostics Inc
Quest Diagnostics Incorporated (NYSE: DGX) is a leading U.S. diagnostic information services company headquartered in Secaucus, New Jersey, and listed on the NYSE in the United States. The company operates a broad clinical laboratory network and a large patient-access footprint, serving physicians, hospitals, health plans, employers, and consumers. Its model is centered on turning laboratory testing into actionable clinical information, combining test execution, logistics, digital ordering, and results delivery across a wide range of medical specialties. ([questdiagnostics.com](https://www.questdiagnostics.com/our-company/about-us?utm_source=openai))
Founded in 1967, Quest Diagnostics grew through decades of consolidation in the U.S. laboratory-services market and has established itself as one of the country’s benchmark diagnostic platforms. The company describes itself as the world’s leading provider of diagnostic information services, and its scale is notable: it says it serves about one in three adult Americans each year and roughly half of U.S. physicians and hospitals. That reach gives Quest meaningful operating leverage, a strong brand in routine and specialized testing, and a durable position in the care pathway. ([questdiagnostics.com](https://www.questdiagnostics.com/our-company/about-us?utm_source=openai))
Read moreShow less
Quest’s core business lines include routine blood chemistry, hematology, pathology, women’s health, infectious disease testing, oncology, genetics, and other specialty diagnostics. In addition to serving independent clinicians and health systems, it supports large enterprise customers through health-plan, employer, and consumer channels, as well as collaborative lab models with hospitals and integrated delivery networks. This mix provides a balance between high-volume commodity testing and higher-complexity specialty services, which is important in a sector where pricing pressure is offset by scale, workflow integration, and clinical relevance. ([questdiagnostics.com](https://www.questdiagnostics.com/our-company/about-us?utm_source=openai))
From a competitive standpoint, Quest is one of the major national players in U.S. diagnostics. Its advantages are scale, geographic coverage, broad test menus, logistics capabilities, and the ability to integrate acquisitions and strategic partnerships. The company has also emphasized digital and operational transformation, including collaborations designed to improve order-to-cash workflows and customer experience. Management’s messaging in 2025 and 2026 points to a strategy focused on sustainable growth, disciplined capital allocation, and deeper integration with healthcare providers and consumer health platforms. ([ir.questdiagnostics.com](https://ir.questdiagnostics.com/press-releases/press-release-details/2025/Quest-Diagnostics-to-Highlight-Strategic-Priorities-to-Drive-Sustainable-Growth-and-Deliver-Long-term-Shareholder-Value-at-2025-Investor-Day/default.aspx?utm_source=openai))
Recent developments reinforce that positioning. In February 2026, Quest reported strong fourth-quarter and full-year 2025 results, raised its 2026 guidance, and increased its quarterly dividend. In August 2025, it completed the acquisition of select clinical testing assets from Fresenius Medical Care’s Spectra Laboratories, strengthening its renal-testing franchise and related dialysis-service exposure. In April 2026, the company again posted revenue and earnings growth for the first quarter, indicating continued demand for its diagnostic services in the U.S. market. ([ir.questdiagnostics.com](https://ir.questdiagnostics.com/press-releases/press-release-details/2026/Quest-Diagnostics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results--Provides-Guidance-for-Full-Year-2026-Increases-Quarterly-Dividend-7-5-to-0-86-Per-Share/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
